

To Whom It May Concern:

RE : Biologic treatment (Infliximab and Adalimumab) for Crohn's Disease.

I support the current application being considered to change the current process, where prescribers are required to request approval either in writing or via phone to prescribe these items under the PBS, as opposed to an Authority Required (Streamlined) listing which requires a prescriber to enter a four digit approval number relating to a specific indication.

The current process of a written application for approval, followed by written applications for continuation, is lengthy and changing to a Streamlined listing would greatly enhance efficiency, patient throughput and productivity. The time and cost saving would be considerable.

We look forward to hearing the outcome,

Dr Nicole Walker

Gastroenterologist

Gold Coast University Hospital